Work

Decreased NSG3 enhances PD-L1 expression by Erk1/2 pathway to promote pancreatic cancer progress.

Year: 2021

Type: article

Abstract: . Importantly, NSG3 prevented Erk1/2 phosphorylation to inhibit PD-L1 expression. Additionally, NSG3 and an immune checkpoint inhibitor anti-PD-1 antibody acted synergistically, which enhanced the efficacy of the inhibitor. NSG3 inhibited PD-L1 expression by suppressing Erk1/2 phosphorylation to improve the immune response to PC. NSG3 is, therefore, a potential new diagnostic and prognostic marker, particularly useful in immune checkpoint blockade therapy.

Source: PubMed

Authors: Xigang Xia, Ran Li, Peng Zhou, Zhixiang Xing, Chao Lu, Zhida Long, Feiyang Wang, Rui Wang

Institutions: Yangtze University, Zhongnan Hospital of Wuhan University, Wuhan Union Hospital, Jingzhou Central Hospital, Huazhong University of Science and Technology, Guiyang Medical University, Shanghai Jiao Tong University, Shanghai First People's Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W3145212084

FWCI: 0.7

Cites: 34

Cited by: 7

Related to: 10